Search

Eric G Marcusson

from San Francisco, CA
Age ~59
Get Report
Also known as:
Eric N
Phone and address:
260 King St #727, San Francisco, CA 94107
(760) 468-1767
Related to:
Angela R Stott, 52Wendy L Scott, 72Joyce A Parks, 84David Zava, 76Brandon FanelliDavid Zava, 56Cynthia Zava, 67
Connected to:
Ashley Marcussen, 30Timothy T Marcussen, 57Julie Marcuz, 38Brian S Marcuzzo, 58James H Marcuzzo, 43Jean H Marcuzzo, 70John R Marcuzzo, 31Alex J Marcy, 32Alexandra C Marcy, 37Bradford E Marcy, 46

Eric Marcusson Phones & Addresses

  • 260 King St #727, San Francisco, CA 94107 (760) 468-1767
  • 260 King St, San Francisco, CA 94107
  • 8803 Gilman Dr, La Jolla, CA 92037 (858) 453-0477
  • 9565 Genesee Ave, San Diego, CA 92121 (858) 453-0477
  • 6369 Caminito Del Pastel, San Diego, CA 92111 (858) 453-0477
  • 1545 Ranchwood Ln, Fallbrook, CA 92028 (760) 453-0477
  • Carlsbad, CA
  • 1545 Ranchwood Ln, Fallbrook, CA 92028

Work

Company: Biotechnology industry Jul 2013 Position: Consultant

Education

Degree: Ph.D. School / High School: University of California, San Diego - School of Medicine 1990 to 1995 Specialities: Biomedical Sciences

Skills

Drug Discovery • Molecular Biology • Cancer • Genomics • Oncology • Cell • Assay Development • Biotechnology • Life Sciences • In Vivo • Cell Biology • Animal Models • Clinical Development • Clinical Trials • Transfection • Lifesciences • Biochemistry • Mirna • Cell Culture • Pharmacology • Drug Development • Biopharmaceuticals • Chemistry • Genetics • Pharmaceutical Industry • Validation

Emails

m***[email protected]

Industries

Biotechnology

Resumes

Resumes

Eric Marcusson Photo 1

Sab Member

View page
Location:
San Francisco, CA
Industry:
Biotechnology
Work:
Biotechnology Industry since Jul 2013
Consultant
Regulus Therapeutics Jan 2011 - May 2013
Senior Director, Oncology and Basic Mechanisms
Regulus Therapeutics - San Diego, CA Sep 2007 - Dec 2010
Director, Drug Discovery
Isis Pharmaceuticals May 2004 - Sep 2007
Director, Antisense Drug Discovery
Isis Pharmaceuticals - Carlsbad, CA Jan 2003 - Apr 2004
Associate Director, Antisense Drug Discovery
Education:
University of California, San Diego - School of Medicine 1990 - 1995
Ph.D., Biomedical Sciences University of California, San Diego 1983 - 1988
BA - Magna Cum Laude, Cell Bioogy and Physiological Psychology
Skills:
Drug Discovery
Molecular Biology
Cancer
Genomics
Oncology
Cell
Assay Development
Biotechnology
Life Sciences
In Vivo
Cell Biology
Animal Models
Clinical Development
Clinical Trials
Transfection
Lifesciences
Biochemistry
Mirna
Cell Culture
Pharmacology
Drug Development
Biopharmaceuticals
Chemistry
Genetics
Pharmaceutical Industry
Validation

Publications

Us Patents

Antisense Modulation Of Fas Mediated Signaling

View page
US Patent:
6653133, Nov 25, 2003
Filed:
Sep 18, 2000
Appl. No.:
09/665615
Inventors:
Nicholas M. Dean - Olivenhain CA
Eric G. Marcusson - San Diego CA
Jacqueline Wyatt - Encinitas CA
Assignee:
ISIS Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
C07H 2104
US Classification:
435375, 435 6, 435 911, 435 913, 435325, 536 231, 536 232, 536 243, 536 2431, 536 2433, 536 245
Abstract:
Compounds, compositions and methods are provided for inhibiting Fas mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding Fas, FasL and Fap-1. Methods of using these antisense compounds for inhibition of Fas, FasL and Fap-1 expression and for treatment of diseases, particularly autoimmune and inflammatory diseases and cancers, associated with overexpression or constitutive activation of Fas, FasL or Fap-1 are provided.

Modulation Of Hif1Α And Hif2Α Expression

View page
US Patent:
7217572, May 15, 2007
Filed:
Nov 21, 2003
Appl. No.:
10/719370
Inventors:
Donna T. Ward - Murrieta CA, US
Kenneth W. Dobie - Del Mar CA, US
Eric G. Marcusson - San Diego CA, US
Susan M. Freier - San Diego CA, US
Assignee:
Isis Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
C12N 15/58
C12Q 1/68
C12P 19/34
C07H 21/02
C07H 21/04
US Classification:
435458, 435 6, 435 911, 435 9131, 435455, 536 231, 536 245
Abstract:
Compounds, compositions and methods are provided for modulating the expression of HIF1α and/or HIF2α. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1α and HIF2α. Methods of using these compounds for modulation of HIF1α and/or HIF2α expression and for diagnosis and treatment of disease associated with expression of HIF1α and/or HIF2α are provided.

Modulation Of Eif4E Expression

View page
US Patent:
7425544, Sep 16, 2008
Filed:
Sep 17, 2004
Appl. No.:
10/571339
Inventors:
Kenneth Dobie - Del Mar CA, US
Eric G. Marcusson - San Francisco CA, US
Eric E. Swayze - Carlsbad CA, US
Balkrishen Bhat - Carlsbad CA, US
Jeremy Richard Graff - Indianapolis IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
ISIS Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
A61K 31/70
C07H 21/02
C07H 21/04
C12N 5/00
C12Q 1/68
US Classification:
514 44, 536 241, 536 245, 536 231, 435 6, 435375, 435377
Abstract:
Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.

Modulation Of Eif4E Expression

View page
US Patent:
7601700, Oct 13, 2009
Filed:
Aug 1, 2008
Appl. No.:
12/184379
Inventors:
Kenneth Dobie - Del Mar CA, US
Eric G. Marcusson - San Francisco CA, US
Eric E. Swayze - Carlsbad CA, US
Balkrishen Bhat - Carlsbad CA, US
Jeremy Richard Graff - Indianapolis IN, US
Assignee:
Eli Lilly and Company - Indianapolis IN
ISIS Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
C07H 21/02
C07H 21/04
A61K 31/70
C12N 5/00
C12Q 1/68
US Classification:
514 44, 435 6, 435375, 435377, 536 231, 536 241, 536 245
Abstract:
Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.

Modulation Of Hif-1 Beta Expression

View page
US Patent:
7618947, Nov 17, 2009
Filed:
Aug 25, 2005
Appl. No.:
11/213593
Inventors:
Eric G. Marcusson - San Francisco CA, US
Scott W. Henry - Cardiff CA, US
Youngsoo Kim - San Diego CA, US
Kenneth W. Dobie - Del Mar CA, US
Assignee:
Isis Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
A61K 31/70
C07H 21/02
C07H 21/04
C12Q 1/68
US Classification:
514 44, 435 6, 435375, 435377, 536 231, 536 241, 536 245
Abstract:
Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided.

Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas

View page
US Patent:
7683036, Mar 23, 2010
Filed:
Jul 30, 2004
Appl. No.:
10/909125
Inventors:
Christine Esau - La Jolla CA, US
Bridget Lollo - Encinitas CA, US
C. Frank Bennett - Carlsbad CA, US
Susan M. Freier - San Diego CA, US
Richard H. Griffey - Vista CA, US
Brenda F. Baker - Carlsbad CA, US
Timothy A. Vickers - Oceanside CA, US
Eric G. Marcusson - San Diego CA, US
Erich Koller - Carlsbad CA, US
Eric E. Swayze - Carlsbad CA, US
Ravi Jain - Carlsbad CA, US
Balkrishen Bhat - Carlsbad CA, US
Eigen Peralta - Chula Vista CA, US
Assignee:
Regulus Therapeutics Inc. - Carlsbad CA
International Classification:
A61K 31/70
C07H 21/04
US Classification:
514 44, 536 245, 536 231
Abstract:
Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.

Identification Of Novel Pathways, Genes And Promoter Motifs Regulating Adipogenesis

View page
US Patent:
7759318, Jul 20, 2010
Filed:
May 27, 2005
Appl. No.:
11/140437
Inventors:
Ranjan Perera - Carlsbad CA, US
Seongjoon Koo - San Marcos CA, US
Nicholas M. Dean - Olivenhain CA, US
Eric G. Marcusson - San Francisco CA, US
Assignee:
Isis Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
A61K 48/00
US Classification:
514 44, 536 245, 536 241, 536 2431
Abstract:
The present invention provides compounds, compositions, and methods for identification of motifs within regulatory regions of genes involved in adipogenesis and adipocyte differentiation. Compounds and compositions are provided for modulating expression of nuclear receptor/transcription factor-regulated genes. Methods for modulating the function of PPAR-γ as well as PPAR-γ-regulated gene promoters, and methods of using oligomeric compounds for diagnosis and treatment of diseases such as obesity and diabetes are also provided.

Modulation Of Hif1-Beta Expression

View page
US Patent:
7799764, Sep 21, 2010
Filed:
Oct 13, 2009
Appl. No.:
12/578468
Inventors:
Eric G. Marcusson - San Diego CA, US
Scott W. Henry - Cardiff CA, US
Youngsoo Kim - San Diego CA, US
Kenneth Dobie - Del Mar CA, US
Assignee:
Isis Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
A61K 31/70
C07H 21/02
C07H 21/04
C12Q 1/68
C12N 5/00
US Classification:
514 44A, 435 6, 435375, 435377, 536 231, 536 241, 536 245
Abstract:
Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided.
Control profile
Eric G Marcusson from San Francisco, CA, age ~59 Get Report